Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)

PHASE3CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

October 17, 2017

Primary Completion Date

August 14, 2018

Study Completion Date

April 2, 2019

Conditions
Varicella
Interventions
BIOLOGICAL

VARIVAX® PE34 Process

Varicella virus vaccine live manufactured with a new passage extension process (PE34)

BIOLOGICAL

VARIVAX® 2016 Commercial Process

Varicella virus vaccine live manufactured with the 2016 commercial process

BIOLOGICAL

M-M-R II®

Measles, Mumps, and Rubella virus vaccine live

Trial Locations (37)

13057

Child Health Care Associates ( Site 0045), East Syracuse

16148

Kid's Way Pediatrics ( Site 0047), Hermitage

22902

Pediatric Research of Charlottesville, LLC ( Site 0039), Charlottesville

27103

Ford, Simpson, Lively & Rice Pediatrics, PLLC ( Site 0037), Winston-Salem

28607

Blue Ridge Pediatric & Adolescent Medicine ( Site 0001), Boone

29406

Palmetto Pediatrics, PA ( Site 0023), Charleston

29414

Coastal Pediatric Research ( Site 0006), Charleston

32746

Children's Research at Altamonte Pediatric Associates ( Site 0040), Lake Mary

33606

University of South Florida ( Site 0042), Tampa

35205

Alabama Clinical Therapeutics ( Site 0018), Birmingham

37660

Holston Medical Group Pediatrics ( Site 0024), Kingsport

40004

Kentucky Pediatric/Adult Research Inc ( Site 0012), Bardstown

40202

University of Louisville: Pediatric Clinical Trials Unit ( Site 0025), Louisville

44121

Senders Pediatrics ( Site 0034), Cleveland

45414

Ohio Pediatric Research Association ( Site 0035), Dayton

64114

The Center For Pharmaceutical Research PC ( Site 0011), Kansas City

66604

Cotton O'Neil Research Center ( Site 0014), Topeka

67010

Heartland Research Associates, LLC ( Site 0029), Augusta

67114

Heartland Research Associates, LLC ( Site 0015), Newton

71037

ACC Pediatric Research ( Site 0041), Haughton

72401

Children's Clinic of Jonesboro, PA ( Site 0030), Jonesboro

77055

West Houston Clinical Research Services ( Site 0009), Houston

77375

Pediatric Healthcare of Northwest Houston ( Site 0027), Tomball

77555

University of Texas Medical Branch at Galveston ( Site 0032), Galveston

78705

Benchmark Research ( Site 0005), Austin

80233

IMMUNOe Research Centers ( Site 0046), Thornton

83642

Advanced Clinical Research ( Site 0038), Meridian

84041

Tanner Clinic ( Site 0010), Layton

84067

Wee Care Pediatrics-Roy ( Site 0043), Roy

84075

Wee Care Pediatrics ( Site 0036), Syracuse

84088

Advanced Clinical Research ( Site 0020), West Jordan

84095

J Lewis Research Inc/Jordan River Family Medicine ( Site 0019), South Jordan

84109

J Lewis Research Inc / Foothill Family Clinic ( Site 0016), Salt Lake City

84121

J Lewis Research Inc/Foothill Family Clinic South ( Site 0004), Salt Lake City

90240

Premier Health Research Center, LLC ( Site 0044), Downey

92123

California Research Foundation ( Site 0003), San Diego

92804

Southland Clinical Research Center ( Site 0017), Anaheim

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03239873 - Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03) | Biotech Hunter | Biotech Hunter